Biphenyl compounds useful as Muscarinic Receptor Antagonists, Process for their preparation, Pharmaceutical compositions containing them, their use in the manufacture of a Medicament for the treatment of pulmonary diseases and a method to study a Biological Sample than the C

摘要

Formula compound (1) is the opposite of muscle receptor. Drug synthesis containing such compounds, processes and intermediates, and methods of using these compounds for the treatment of lung diseases. Item 1: a formula compound (1)where: a is 0 or an integer between 1 and 5; each R1 is independently selected from C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, cyano, halo, - OR1a, -C (O) OR1b, -SR1c, -S (O) R1d, -S (O) 2R1e and -NR1fR1g; where each of R1a, R1b, R1c, R1d, R1e, R1f and R1g is independently hydrogen, C1-4 alkyl or phenyl-C1-4alkyl; b is 0 or an integer between 1 and 4; each R2 is independently selected from C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, cyano, halo, -OR2a, -C (O) OR2b, -SR2c, -S (O) R2d, -S (O) 2R2e and -NR2fR2g; where each of R2a, R2b, R2c, R2d, R2e, R2f and R2g is independently hydrogen, C1-4 alkyl or phenyl-C1-4alkyl;W stands for O NWA, where Wa is hydrogen or C1-4 tar; C is an integer of 0 or 1 to 5; each R3 stands for a separate combination of C1-4 or 2 R3 to form c1-3 tar, C2-3 alquinile or oxran-2.3-dilo; m is 0 or 1; R4 is hydrogen gene or C1-4 tar; s is 0, 1 or 2; AR1 refers to a group of phenyl compounds or c3-5 heteromorphic atoms containing 1 or 2 heteromorphic atoms independently selected between oxygen, nitro or sulfur; in this group, the phenyl or heteromorphic ring is replaced by (R5) Q, q is 0 or 1 to 4 integers, and each R5 is in halogen, hydroxy, C1-4 tar or C1-4 alcoxi; t is 0, 1 or 2; n is 0,1 or 2: D is an integer of 0 or 1 to 4; each R6 represents an independent fluorine insect or C1-4 tar; P is 0 or 1; R7 and R8 are independent hydrogen or C1-4 tar; each group of R1, r1a-1g, R2, r2a-2g, R3, R5, R6, R7 or R8 asphalt and alcox is replaced by a fluorine substitute of 1 to 5, or a salt or a solution. Or acceptable stereoisomers for pharmaceutical use Requirement No. 18: a process for preparing a process consisting of any one of 1 and 14 requirements, characterized by (a) reacting a compound of a formula (2),Or salt, a formula compound (3),Z1 represents a factory group, or (b) separates a compound (4) from the formula,Containing a formula compound (5),Or a reaction derivative; or (c) a formula compound (6) reacts,Z2 represents an outgoing group, consisting of a formula (7);(d) Reacting a formula compound (2) with a formula compound (8),In the presence of a reducing agent; or (E) reacting a formula compound (9),In the presence of a reducing agent, a formula compound (7) reacts; or (f) reacts a formula compound (10),R'es h, CH3 o-ch2ch3, which contains a formula compound: nhr7r8, indicating a formula compound (1). Labor requirement 21: a method of studying a biological system or sample, characterized by its inclusion of a muscle receptor, including: (a) linking the biological system or sample to compounds in labor requirements 1 to 14; and (b) determining the effect of a compound on the biological system or sample.